Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-077809
Filing Date
2025-08-13
Accepted
2025-08-13 21:40:59
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18481
2 EXHIBIT A tm2523370d1_ex99-a.htm EX-99.A 8781
  Complete submission text file 0001104659-25-077809.txt   28906
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Subject) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88628 | Film No.: 251213875
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ILJIN BUILDING, 45 MAPO-DAERO, MAPO-GU SEOUL M5 121-716
Business Address ILJIN BUILDING, 45 MAPO-DAERO, MAPO-GU SEOUL M5 121-716 82-2-707-9742
ILJIN SNT Co., Ltd. (Filed by) CIK: 0001772596 (see all company filings)

EIN.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231